Mode
Text Size
Log in / Sign up
Phase 4 Completed N=108 Randomized Triple-blind Other

Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

Neuromuscular Blockade
Source: ClinicalTrials.gov NCT03039543 ↗
Enrolled (actual)
108
Serious AEs
0.0%
Results posted
May 2018
Primary outcomePrimary: Number of Participants Attaining a 5 (Optimal) Surgical Condition Score — 16; 38 Participants
◆ Published Evidence
Highly cited
258citations · ~22 / year
Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block.
British journal of anaesthesia · 2014 · Open access · High-confidence link

Summary

Transurethral resection of the bladder tumor (TURB) for bladder tumor excision is the mainstream treatment. However, the beneficial effects of sugammadex after general anesthesia for TURB have not been thoroughly evaluated. Investigators hypothesized that deep NMB and the use of sugammadex as a reversal agent may be associated with better endoscopic surgical condition and recovery profile compared with moderate NMB during TURB. This study was designed to compare patients with deep neuromuscular blockade (NMB) with moderate NMB during transurethral resection of the bladder tumor (TURB) in terms of surgical condition and postoperative recovery.

Linked Publications (3)

  • Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block.
    British journal of anaesthesia · 2014 · 258 citations · Open access · High-confidence link
  • Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis.
    British journal of anaesthesia · 2007 · 238 citations · High-confidence link
  • Randomized Clinical Trial of Moderate Versus Deep Neuromuscular Block for Low-Pressure Pneumoperitoneum During Laparoscopic Cholecystectomy.
    World journal of surgery · 2016 · 72 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Attaining a 5 (Optimal) Surgical Condition Score
16; 38
SECONDARY
Incidence of Postoperative Residual Curarization
0; 0
SECONDARY
Recovery Time (PACU Discharge)
15; 15
SECONDARY
the Incidence of Desaturation
0; 0
SECONDARY
Other Postoperative Adverse Events
0; 0

Eligibility Criteria

Inclusion Criteria

  • Patients aged more than 18 years
  • American Society of Anesthesiologists (ASA) physical status I and II
  • scheduled to undergo elective Transurethral resection of the bladder tumor (TURB)

Exclusion Criteria

  • history of neuromuscular, renal, or hepatic disease
  • a body mass index (BMI) of C 30.0 kg/m2
  • treatment with drugs known to interfere with neuromuscular function
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03039543) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search